Abstract: Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.

Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.

Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.

Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.

Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.

Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.

Abstract: Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Abstract: Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.

Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Abstract: The present invention relates to chimeric anti-CD14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-CD 14 antibodies in research, diagnostic, and therapeutic applications. In one embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 1 and a variable heavy chain of SEQ ID NO: 2 (isolated from the hybridoma clone 18D11). In another embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 3 and a variable heavy chain of SEQ ID NO: 4 (isolated from the hybridoma clone Mil2).

Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.

Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.

Abstract: Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating Globo-H-positive cancer.

Abstract: Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.

Abstract: Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

Abstract: Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of TIGIT, Flg2 and/or IL-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of autoimmune diseases and/or inflammation (e.g., caused by parasitic infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of asthma, allergy, and/or atopy. Methods for identifying patients who are more likely to be responsive to and benefit from an immunotherapy that targets TIGIT, Fgl2 and/or IL-33 are also described herein.

Abstract: The present invention provides an antibody that can react with chondroitin sulfate E at a high specificity and that can be used for, for example, the detection, isolation, and so forth, of specific sulfated polysaccharides. The present invention relates to a novel anti-chondroitin sulfate E antibody that reacts with chondroitin sulfate E and does not react with chondroitin sulfate A, does not react with chondroitin sulfate B, and does not react with chondroitin sulfate D.

Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: The present application provides polyanionic and non-ionic cyclodextrin-based compounds, and methods of manufacturing them. The compounds comprise a negatively-charged or neutral moiety (and, for polyanionic compounds, a suitable counter cation), one or more linkers, optionally one or more bridging groups, a cyclodextrin, and one or more substituents on the cyclodextrin. The compounds can be used in pharmaceutical compositions, and as excipients or carriers of guest molecules.

Abstract: The invention mainly pertains to a method for heat treating a composition [composition (C)] which contains at least one melt-processible perfluoropolymer [polymer (F)] formed of tetrafluoroethylene (TFE) copolymer with one or more perfluorinated comonomers [comonomer (F)] containing at least one unsaturation of ethylene type in amounts from 0.5% to 13% by weight, preferably from 0.6% to 11% by weight, and more preferably from 0.8% to 9% by weight; said polymer (F) possessing reactive end groups comprising at least one of the group consisting of hydrogen atoms, oxygen atoms and ethylenically unsaturated double bonds in an amount of at least 4.5 mmol/kg, the process comprising at least the step of heat-treating the composition (C) at a temperature of at least 260° C.

Abstract: A process for preparing moisture curable compounds and moisture curable compositions prepared from the product of that process is provided.

Abstract: Provided are a novel metallocene compound, a catalyst composition including the same, and a method of preparing a polyolefin using the same. The metallocene compound according to the present invention and the catalyst composition including the same may be used for the preparation of a polyolefin, may have excellent polymerization ability, and may produce a polyolefin having an ultra-high molecular weight. In particular, when the metallocene compound according to the present invention is employed, an olefin-based polymer having an ultra-high molecular weight may be polymerized because the metallocene compound shows high polymerization activity even when it is supported on a support.

Abstract: A catalyst system for the polymerization of olefins may include a first solid catalytic component and a second solid catalytic component. The first solid catalytic component may include: a spherical MgCl2-xROH support; a group 4-8 transition metal; and a diether internal electron donor. The second solid catalytic component may include: a spherical MgCl2-xROH support; a group 4-8 transition metal; and a diether internal electron donor. The first solid catalytic component produces a propylene homopolymer having a Xylene Solubles (XS) value of greater than 2 wt %; and the second solid catalytic component produces a propylene homopolymer having a XS value of less than 2 wt %. The second catalytic component may act as an external electron donor during use, and embodiments herein do not require use of any additional external electron donors to control polymerization and reliably vary the properties of the resulting polymer.

Abstract: The present invention provides a polytetrafluoroethylene powder having high dispersibility in lubricants. The polytetrafluoroethylene powder includes polytetrafluoroethylene containing a tetrafluoroethylene unit alone or a tetrafluoroethylene unit and a modifying monomer unit based on a modifying monomer copolymerizable with the tetrafluoroethylene, and has a specific surface area of 32 m2/g or larger.

Abstract: The present invention describes the preparation of highly-performing “Acrylamide Free” polyelectrolytic polymers by using not toxic monomers and the way such new monomers can be advantageously used in the field of several civil and/or industrial applications. The new polyelectrolytic polymers developed herein can be then used both as replacement of the common acrylamide-based polymers and in the applications wherein the absence of residual toxic polymerization monomers is requested.

Abstract: A method for producing an olefin polymer, in which an olefin compound is polymerized in the presence of a Lewis acid catalyst at a temperature of 0° C. or lower to obtain an olefin polymer, the method comprising a step of feeding a raw material liquid including the olefin compound to a reactor provided with a cooling unit, a step of polymerizing the olefin compound in the reactor to obtain a reaction liquid including the olefin polymer, a deactivation step of adding a deactivator to the reaction liquid taken out from the reactor to deactivate the Lewis acid catalyst, and a step of supplying the reaction liquid after the deactivation step to a cold recovery unit to recover cold from the reaction liquid, wherein the amount of the Lewis acid catalyst is 0.5×10?3 to 1.0×10?1 mol % based on the total amount of the olefin compound.

Abstract: The following are provided: a water-absorbent resin in which, in the formation of an absorbent material forming an absorbent article, dispersion is satisfactory even in a moisture absorption state, which prevents the occurrence of troubles at the time of manufacturing of the absorbent article and which allows efficient manufacturing; and an absorbent article using an absorbent material containing the water-absorbent resin. The water-absorbent resin according to the present invention is obtained by polymerizing a water-soluble ethylenically unsaturated monomer and performing post-crosslinking thereon with a post-crosslinking agent, and the water-absorbent resin satisfies the requirements below: (A) yellow index is 5.0 or less; and (B) gel strength is 1800 Pa or less.

Abstract: With respect to water-absorbent resins, there are provided a method of manufacturing a water-absorbent resin having an appropriate BET specific surface and a water-absorption rate and a water-absorbing agent and an absorbent article that are formed by using the water-absorbent resin. In a first aspect of the present invention, when reverse phase suspension polymerization of two steps or more is performed on a water-soluble ethylenically unsaturated monomer in a hydrocarbon dispersion medium in the presence of at least an azo compound, a peroxide and an internal-crosslinking agent, the used amount of the internal-crosslinking agent at the time of the polymerization of a first step is adjusted to fall within a range of 0.015 to 0.

Abstract: A warewashing detergent composition is provided for use for in cleaning of alkaline sensitive metals such as aluminum or aluminum containing alloys. The compositions include alternatives to sodium tripolyphosphate and/or other phosphorous containing raw materials, while retaining cleaning performance and corrosion prevention. According to the invention, high molecular weight polyacrylates (polyacrylic acid homopolymers) with a molecular weight of at least about 5000 are used as corrosion inhibitors and can be included for aluminum protection in a number of different detergent compositions.

Abstract: The invention provides a composition comprising an ethylene-based polymer, comprising at least the following: A) a unit derived from Carbon Monoxide (CO); and B) a unit derived from at least one Rheology Modifying Agent (RMA) selected from the following RMA1, RMA2, RMA3, RMA4, RMA5, each as described herein, or a combination thereof.

Abstract: The present invention pertains to a metallocene catalyst based on a transition metal of groups 4 or 5 of the periodic table prepared by the immobilization of a metallocene complex on a support modified with hybrid soluble silica, prepared by a non-hydrolytic sol-gel process. There is also described a process for preparing said catalyst. The supported metallocene catalyst of the present invention has the advantages of high catalytic activity, morphology, besides the fact of producing copolymers of ethylene with alpha-olefins having molecular behavior that will bring benefits in mechanical properties, such as resistance to tearing, piercing and impact, as well as improved optical and weldability properties.

Abstract: A block copolymer includes a first polymer block and a second polymer block having different structures, and one of the first polymer block and the second polymer block has a halogen-substituted structure.

Abstract: An adhesive composition is disclosed. The adhesive composition comprises an epoxy-containing component; rubber particles having a core-shell structure; and a curing component comprising a mixture of an amine-containing compound substantially free of hydroxyl functional groups and a polymeric phenol-containing compound, wherein the amine-containing compound comprises primary and/or secondary amino groups, and wherein the curing component chemically reacts with the epoxy-containing component upon activation from an external energy source. Also disclosed are methods of preparing the adhesive composition and for forming a bonded substrate with the adhesive composition. Further disclosed are curing components for an adhesive composition and methods of making the curing components.

Abstract: A process for preparing aqueous polyurethane solvent-free uses an acrylate monomer instead of acetone to dilute a prepared polyurethane prepolymer, not only the monomer can be added without cooling, but also the prepolymer has good dispersal and is favorable to subsequent dispersion in water while preventing coagulation and acetone residual; additionally, the invented process let the aqueous polyurethane become modified by acrylic grafting may improve the aqueous polyurethane being excellent in terms of mechanical strength, heat resistance and water resistance.

Abstract: Principles and embodiments of the present invention relate generally to thermoplastic polyurethane materials having controlled and improved stiffness and/or flexibility, and methods to prepare them. The thermoplastic polyurethanes described herein having superior stiffness and softening properties may be fabricated into film, tubing, and other forms of medical devices. The thermoplastic polyurethanes comprise: an aromatic diisocyanate excluding non-aromatic diisocyanates; at least one polyglycol; and a chain extender comprising at least one side-chain branching diol and excluding linear diols.

Abstract: 1) Specific polyurethane prepolymer (PP2) comprising at least two terminal (2-oxo-1,3-dioxolan-4-yl)methyl carbamate groups of low viscosity, its preparation process and its use in the manufacture of an adhesive composition. 2) Multicomponent system comprising, as first component (A), a composition comprising at least one such polyurethane prepolymer and, as second component (B), a composition comprising at least one curing agent having at least two primary amine (—NH2) groups (B1). 3) Process for assembling materials employing the polyurethane prepolymer (PP2) according to the invention.

Abstract: A silicone-modified epoxy resin which yields a cured product having low gas permeability and excellent strength; a composition of the silicone-modified epoxy resin; and an epoxy resin cured product obtainable by curing the composition, are provided. An epoxy resin represented by the following Formula (1): wherein R1 represents a hydrocarbon group having 1 to 6 carbon atoms; X represents an organic group having a norbornane epoxy structure, or a hydrocarbon group having 1 to 6 carbon atoms; n represents an integer from 1 to 3; plural R1s and plural Xs present in the formula may be respectively identical or different; and two or more of plural Xs represent an organic group having a norbornane epoxy structure.

Abstract: The present invention provides a method of preparing an amine-functionalized (e.g. amine-terminated) polyaryletherketone polymer, or imide- or sulphone-copolymer thereof and amine-protected analogues thereof, said method comprising the step of polymerizing a monomer system in a reaction medium comprising a capping agent comprising —NR2, —NRH or a protected amine group.

Abstract: The invention relates to a method of isolation of polyhydroxyalkanoates from biomass fermented by microorganisms producing polyhydroxyalkanoates and/or from biomass containing at least one crop-plant producing polyhydroxyalkanoates in which from the biomass which, if fermented, is first inspissated by the isolation from a fermentation medium to a dry matter content of at least 20%, polyhydroxyalkanoates are extracted with an extraction agent based on chlorinated hydrocarbon, whereupon from the extraction solution thus obtained an extract is separated, from which the extraction agent is removed and polyhydroxyalkanoates precipitate. Prior to the extraction of polyhydroxyalkanoates, components of the biomass other than polyhydroxyalkanoates are extracted from the biomass by means of an extraction agent based on alkyl alcohol having 2 to 4 carbon atoms in the chain, which is added to the biomass in a weight ratio of 1:0.

Abstract: A hydrophilic polymer derivative having a cyclic benzylidene acetal linker represented by the following formula (1): wherein R1 and R6 are each independently a hydrogen atom or a hydrocarbon group; R2, R3, R4 and R5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; X1 is a chemically reactive functional group; P is a hydrophilic polymer, s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 8; and Z1 and Z2 are each independently a selected divalent spacer.

Abstract: The invention relates to copolyamides which are formed from a diamine component, a dicarboxylic acid component and possibly a lactam- and/or ?-amino acid component. Furthermore, the invention relates to a polyamide moulding compound which comprises at least one of these copolyamides. Moulded articles produced from these moulding compounds are used in the automobile field, in the domestic field, in measuring-, regulating- and control technology or in mechanical engineering.

Abstract: Hydroxypolyamides, hydroxypolyamide products, and post-hydroxypolyamides are disclosed as gel forming agents. Hydroxypolyamides and post-hydroxypolyamides are prepared from known methods. Hydroxypolyamide products are produced from a modified polymerization procedure which utilizes strong base for deprotonation of ammonium salts from the esterification of stoichiometrically equivalent polyacid:polyamine salts. The hydroxypolyamide products are capable of gel formation at lower concentrations than hydroxypolyamides and post-hydroxypolyamides from the known methods of preparation, and are therefore superior gel forming agents.